The recent surge in capital into niche pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and impressive returns is undeniable, the associated risks are also significant.… Read More